MARC Record from marc_columbia

LEADER: 03641cam a2200721 a 4500
001 6216043
005 20221122005244.0
008 030324s2002 fr a b i001 0 eng
016 7 $a101175150$2DNLM
019 $a51907296
020 $a9283212827
020 $a9789283212829
029 0 $aNLM$b101175150
029 1 $aNLGGC$b24689539X
035 $a(OCoLC)ocm52515637
035 $a(OCoLC)52515637$z(OCoLC)51907296
035 $a(NNC)6216043
035 $a6216043
040 $aNLM$cNLM$dHNT$dCOU$dCUY$dBAKER$dNLGGC$dLVB$dCGC
042 $anlmcopyc
050 4 $aRC267.A1$b.I2 v.82
060 00 $aW1$bIA21I v.82 2002
060 10 $aQZ 202$bS6937 2002
084 $a44.81$2bcl
245 00 $aSome traditional herbal medicines, some mycotoxins, naphthalene and styrene.
260 $a[Lyon, France] :$bInternational Agency for Research on Cancer ;$aGeneva :$bDistributed by IARC Press and by the World Health Organization,$c2002.
300 $avi, 590 pages :$billustrations ;$c24 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
490 1 $aIARC monographs on the evaluation of carcinogenic risks to humans,$x1017-1606 ;$vv. 82
500 $a"This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 12-19 February 2002."
500 $aAt head of title: World Health Organization, International Agency for Research on Cancer.
504 $aIncludes bibliographical references and cumulative index.
650 0 $aHerbs$xTherapeutic use$vCongresses.
650 0 $aMycotoxins$vCongresses.$0http://id.loc.gov/authorities/subjects/sh2010103004
650 0 $aNaphthalene$vCongresses.
650 0 $aStyrene$vCongresses.
650 12 $aCarcinogens.$0https://id.nlm.nih.gov/mesh/D002273
650 22 $aEnvironmental Exposure$xadverse effects.$0https://id.nlm.nih.gov/mesh/D004781Q000009
650 22 $aMycotoxins$xadverse effects.$0https://id.nlm.nih.gov/mesh/D009183Q000009
650 22 $aNaphthalenes$xadverse effects.$0https://id.nlm.nih.gov/mesh/D009281Q000009
650 22 $aPlant Preparations$xadverse effects.$0https://id.nlm.nih.gov/mesh/D028321Q000009
650 22 $aRisk Assessment.$0https://id.nlm.nih.gov/mesh/D018570
650 22 $aStyrene$xadverse effects.$0https://id.nlm.nih.gov/mesh/D020058Q000009
650 14 $aHerbal medicines$xCarcinogenicity$vCongresses.
650 14 $aHerbal medicines$xToxicology$vCongresses.
650 14 $aMycotoxins$xCarcinogenicity$vCongresses.
650 14 $aMycotoxins$xToxicology$vCongresses.
650 14 $aNaphthalene$xCarcinogenicity$vCongresses.
650 14 $aNaphthalene$xToxicology$vCongresses.
650 14 $aStyrene$xCarcinogenicity$vCongresses.
650 14 $aStyrene$xToxicology$vCongresses.
650 17 $aPlantaardige geneesmiddelen.$2gtt
650 17 $aCarcinogeniteit.$2gtt
650 6 $aHerbes$xEmploi en thérapeutique$vCongrès.
650 6 $aMycotoxines$xCancérogénicité$vCongrès.
650 6 $aNaphtalène$xCancérogénicité$vCongrès.
650 6 $aStyrène$xCancérogénicité$vCongrès.
710 2 $aIARC Working Group on the Evaluation of Carcinogenic Risks to Humans.$0http://id.loc.gov/authorities/names/n88087705
710 2 $aInternational Agency for Research on Cancer.$0http://id.loc.gov/authorities/names/n79125097
710 2 $aWorld Health Organization.$0http://id.loc.gov/authorities/names/n79059041
830 0 $aIARC monographs on the evaluation of carcinogenic risks to humans ;$vv. 82.$0http://id.loc.gov/authorities/names/nr96014241
852 80 $boff,hsr$hSerial$iI